HIV Prevention Research at George Washington University
The HPTN strives to evaluate and implement cutting-edge biomedical, behavioral, and structural interventions to reduce the transmission of HIV. Below are a few trials underway at the GW HIV Prevention Trials Network Clinical Research Site.
The studies below are recruiting:
HPTN 094 (INTEGRA)
This study examines the effectiveness of mobile health care strategies for people who inject drugs and are living with or at risk of contracting HIV. This study is currently recruiting and accepting referrals. Email [email protected] if you are interested in learning more. Download IRB approved recruitment materials here.
The studies below are currently in follow up only:
HPTN 083
This is a Phase III study that investigates the safety and efficacy of a long acting, injectable medication (cabotegravir) as HIV pre-exposure prophylaxis (PrEP) among cis-gender men who have sex with men (MSM) and transgender women (TGW). HPTN 083 is the first study to compare the efficacy of injectable cabotegravir to daily oral TDF/FTC (Truvada) for PrEP. HPTN 083 enrolled 4,570 cisgender MSM and TGW who have sex with men at 43 sites in Argentina, Brazil, Peru, United States, South Africa, Thailand and Vietnam. Results showed that long-acting cabotegravir injections were superior to daily oral Truvada in preventing HIV. Cabotegravir injections (brand name “Apretude”) were approved by the FDA for HIV prevention in 2021.
HPTN 101/HVTN 140
This Phase 1 study, conducted in collaboration with the HIV Vaccine Trials Network and the HPTN, investigates if laboratory-created antibodies introduced to the immune system can neutralize many different variants of HIV. This study is currently recruiting and accepting referrals. Email [email protected] if you are interested in learning more.
The studies below have closed completely and the data is being reviewed and written about:
HPTN 061
HPTN 061 was a research study conducted to examine certain strategies which may show promise for slowing the spread of HIV among Black gay, bisexual and other MSM. The study also sought to better understand the lives of Black MSM and how factors in their lives relate to HIV risk. The study began enrolling participants in July 2009 and completed follow up in December 2011.
HPTN 077
HPTN 077 was a study being done to learn more about the safety and acceptability of a drug called cabotegravir (sometimes also referred to as GSK 1265744) when taken orally and injected by HIV uninfected men and women. The study product was provided by GlaxoSmithKline on behalf of ViiV Healthcare.
HPTN 073
HPTN 073 was designed to see if Black men who have sex with men (BMSM) are willing to use Truvada®, a daily pill for pre-exposure prophylaxis (PrEP). HPTN 073 gathered feedback about the experience from the men who elected to use PrEP. PrEP is an HIV prevention method in which people who are HIV-negative take an HIV treatment drug daily to reduce their risk of becoming HIV-infected.
HVTN 704/HPTN 085
The AMP Study tests an experimental antibody against HIV. AMP stands for Antibody Mediated Prevention. This is the idea of giving people antibodies that fight HIV to see if they will protect people from acquiring HIV. The AMP study tests an antibody called VRC01, a manufactured antibody against HIV. This is a new idea for HIV prevention that is related to what has been done in HIV vaccine research. In traditional HIV vaccine studies, people get a vaccine and researchers wait to see if their bodies will make antibodies against HIV in response to the vaccine. In this study, we will skip that step, and give people the antibodies directly.